Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057783 | 0.92 | MAPT (0.33) | HSD17B10KDM4EALDH1A1KLKB1L3MBTL1 | |
| SCHEMBL21503568 | 0.92 | MAPT (0.33) | HSD17B10KDM4EALDH1A1KLKB1L3MBTL1 | |
| SCHEMBL21503393 | 0.82 | KLKB1 (0.35) | KDM4EALDH1A1KLKB1SCD5 | |
| Trifluoroacetic Acid SCHEMBL28524316 | 0.82 | SCD5 (0.40) | KDM4EALDH1A1TRPV1SCD5 | |
| Hydrochloric Acid SCHEMBL21491586 | 0.81 | KLKB1 (0.35) | KDM4EALDH1A1KLKB1LOXL2SCD5 | |
| Hydrochloric Acid SCHEMBL30744393 | 0.81 | KLKB1 (0.35) | KDM4EALDH1A1KLKB1LOXL2SCD5 | |
| SCHEMBL30744336 | 0.78 | SCD5 (0.35) | KLKB1LOXL2SCD5 | |
| SCHEMBL21492743 | 0.78 | SCD5 (0.35) | KLKB1LOXL2SCD5 | |
| Hydrochloric Acid SCHEMBL21492863 | 0.77 | KLKB1 (0.36) | ALDH1A1KLKB1L3MBTL1LOXL2 | |
| Hydrochloric Acid SCHEMBL30744383 | 0.77 | KLKB1 (0.36) | ALDH1A1KLKB1L3MBTL1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | HSD17B10 1245/4885KDM4E 730/4885ALDH1A1 569/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | HSD17B10 1245/4885KDM4E 730/4885ALDH1A1 569/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | HSD17B10 1245/4885KDM4E 730/4885ALDH1A1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.